Advances and Future Perspectives in Diagnosis and Treatment of Urothelial Cell Carcinoma

Dear Colleagues,

The field of research in urothelial cancer has seen significant advances in recent years from diagnosis to treatment, as well as the implementation of prognostic models.

In detail, next-generation sequencing technologies have allowed us to deeply understand the genes most involved in bladder cancer pathogenesis. Non-invasive methods of diagnosis, including liquid biopsies, have seen major advances as well. However, most of these innovative tools need clinical validation.

Moreover, the use of immune checkpoint inhibitor drugs has brought a revolutionary therapeutic approach in patients with advanced and metastatic urothelial cancer.

In parallel, in the last decade, robotic surgery has increasingly been adopted for the treatment of bladder cancer and upper tract urothelial carcinoma with the purpose of decreasing treatment-related morbidity. Lastly, several predictive nomograms and prognostic models have been proposed to improve patient selection and more accurately forecast oncologic outcomes.

Overall, although these developments may provide benefits in terms of improved survival and quality of life, there are several unmet needs before we can effectively cure patients with urothelial cancer and reduce the levels of morbidity associated with treatments.

This Special Issue aims to explore diagnostic and therapeutic advances in the treatment of urothelial carcinoma, including bladder, upper tract, and urethral tumors.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: novel diagnostic tools for bladder cancer, insights in molecular biology of bladder cancer, biomarkers in urothelial cancer, innovative imaging modalities in diagnosis and staging, bladder-sparing treatment options in muscle-invasive bladder cancer, minimally invasive approaches to bladder and upper tract urothelial carcinomas, systemic therapy for high risk urothelial cancers, and predictive and prognostic models in bladder cancer and urethral cancer.

We look forward to receiving your contributions.

Dr. Andrea Mari
Dr. Benjamin Pradere
Dr. Jeremy Yuen-Chun Teoh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.